Quniagolide and Breastfeeding

Summary of use during lactation

Quinagolide is not approved for marketing in the US by the US Food and Drug Administration. It is selective dopamine D2 receptor that reduces serum prolactin. Quinagolide is usually not used during breastfeeding because it suppresses lactation. No published information was found on the use of quinagolide in nursing mothers.

Drug levels in milk and infant serum

Maternal Levels. Relevant published information was not found as of the revision date. Infant Levels. Relevant published information was not found as of the revision date.

Effects in breastfed infants

Relevant published information was not found as of the revision date.

Effects on lactation and breastmilk

A small preliminary study compared quinagolide (CV 205-502) to bromocriptine for 21 days starting in the first day postpartum in mothers who did not wish to breastfeed. Serum prolactin normalized more rapidly with bromocriptine and more women had breast symptoms with quinagolide. Efficacy in suppressing lactation was similar between the groups.[1]

References

1. van der Heijden PF, Kremer JA, Brownell J, Rolland R. Lactation inhibition by the dopamine agonist CV 205-502. Br J Obstet Gynaecol 1991;98:270-6.1673628 PubMed